BioSpace News Archive

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that company management will be presenting at the following investor conferences

Spectral Medical Inc.,, a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, announced its unaudited financial results for the third quarter ended September 30, 2019.

Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced that it will present at two upcoming investor conferences

Pain Care Labs, the industry leader in noninvasive pain relief devices, announced today the presentation of two studies on the company’s focal vibration device (VibraCool®) at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly.

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has entered into a $15 million common stock purchase and registration rights agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a Chicago-based institutional investor and a long standing investor in AzurRx BioPharma, Inc.

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the quarter ended September 30, 2019.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Jeff Albers, Blueprint Medicines’ Chief Executive Officer, will present a company overview at the Jefferies 2019 London Healthcare Conference in London

Hoth Therapeutics, Inc. (Nasdaq: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced, in partnership with the George Washington University (GW),

Incyte Corporation announced that it will present at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 at 8:30 am in New York.

Sema4, a patient-centered health intelligence company, today announced the appointment of Joel Sendek as Chief Financial Officer